Mayne Pharma : - Nextstellis Receives FDA Marketing Exclusivity And Phase III Data Published

Adelaide, Australia and Liege, Belgium - Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce that the novel oral contraceptive Estelle - under the trademark Nextstellis (3 mg drospirenone and 14.2 mg estetrol (E4) tablets) - has been granted marketing exclusivity as a new chemical entity (NCE) from the US Food and Drug Administration (FDA). The exclusivity runs for five years from FDA approval of the New Drug Application for Nextstellis.

Contact:

Rue Saint-Georges 5

4000 Liege

Belgium

Tel: [phone]

Fax: [phone]

Email: [e-mail]

(C) 2021 Electronic News Publishing, source ENP Newswire